INVENTOR SEARCH

=> d ibib abs hitstr l16 1-5

L16 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:988360 HCAPLUS Full-text
DOCUMENT NUMBER: 147:329922
TITLE: Polymorphism of rosiglitazone maleate. Facts and myths
AUTHOR(S): Chodynski, Michal; Fitak, Hanna; Glice, Magdalena M.; Korczak, Katarzyna; Leszczynska, Kinga; Kutner, Andrzej
CORPORATE SOURCE: Zakl. Chem., Inst. Farm., Warsaw, 01-793, Pol.
SOURCE: Przemysl Chemiczny (2007), 86(8), 756-759
CODEN: PRCHAB; ISSN: 0033-2496
PUBLISHER: Wydawnictwo SIGMA-NOT
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Polish
AB A review. Using example of rosiglitazone maleate, a popular drug for the treatment of diabetes mellitus, the authors demonstrate how the crystallization polymorphism of the active pharmaceutical substance can be (ab)used as a potential source for patent claim manipulations. Survey of patent literature on rosiglitazone maleate revealed claims on at least 13 potentially possible polymorphs, while laboratory anal. revealed the existence of only 4 forms.

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:504301 HCAPLUS Full-text
DOCUMENT NUMBER: 145:14914
TITLE: Polymorphism of pharmaceutical substances
AUTHOR(S): Beczkowicz, Hanna; Glice, Magdalena; Korczak, Katarzyna; Kosmacinska, Bozena; Laszcz, Marta; Maruszak, Wioleta
CORPORATE SOURCE: Zakl. Kontroli Jakosci i Anal. Badaw., Inst. Farm., Warsaw, 01-793, Pol.
SOURCE: Przemysl Chemiczny (2006), 85(5), 354-359
CODEN: PRCHAB; ISSN: 0033-2496
PUBLISHER: Wydawnictwo SIGMA-NOT
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Polish
AB A review of anal. aspects of polymorphism of pharmaceutical substances and anal. approaches involving X-ray diffraction, thermal anal. (DSC, TG), and IR spectroscopy.

L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1106857 HCAPLUS Full-text
DOCUMENT NUMBER: 143:392946
TITLE: Preparation of crystalline methanesulfonic acid addition salts of imatinib
INVENTOR(S): Szczepek, Wojciech; Samson-Lazinska, Dorota; Zagrodzki, Bogdan; Glice, Magdalena; Maruszak, Wioleta; Korczak, Katarzyna ; Modzelewski, Ryszard; Lawecka, Marta; Kaczmarek, Lukasz; Szelejewski, Wieslaw; Fraczek, Urszula; Cmoch, Piotr
PATENT ASSIGNEE(S): Instytut Farmaceutyczny, Pol.
SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095379	A2	20051013	WO 2005-PL24	20050402
WO 2005095379	A3	20060518		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1742933	A2	20070117	EP 2005-731354	20050402
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 2007197545	A1	20070823	US 2006-599461	20060929

PRIORITY APPLN. INFO.:

PL 2004-366885	A	20040402
PL 2005-374074	A	20050401
WO 2005-PL24	W	20050402

AB The invention relates to the methanesulfonic acid addition salts of imatinib and to the processes for their preparation In particular, the invention relates to the process for the preparation of imatinib methanesulfonate α-crystal form. Furthermore, the invention is directed to a novel acid addition salt of imatinib with 2 mols. of methanesulfonic acid and the polymorphic forms thereof as well as their pharmaceutical compns. The suspension of imatinib in anhydrous EtOH was heated to 75°, and methanesulfonic acid was slowly added dropwise. EtOAc was added and the mixture was cooled to 30°, while being stirred. The seeds of α-crystal form were added and then the mixture was cooled and stirred at 13-20° for 4 h. The crystals were filtered off, and dried to obtain α-crystal form of imatinib mesylate yield: 65.0%.

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:120908 HCAPLUS Full-text
DOCUMENT NUMBER: 142:198109
TITLE: Process for the preparation of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine an intermediate in the synthesis of the antipsychotic drug quetiapine
INVENTOR(S): Kaczmarek, Lukasz; Badowska-Roslonek, Katarzyna; Stolarczyk, Elzbieta; Szeliejewski, Wieslaw
PATENT ASSIGNEE(S): Helm AG, Germany; Instytut Farmaceutyczny
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012274	A1	20050210	WO 2004-EP51520	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PL 195728	B1	20071031	PL 2003-361347	20030718
EP 1660469	A1	20060531	EP 2004-766244	20040716
EP 1660469	B1	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
AT 371654	T	20070915	AT 2004-766244	20040716
PRIORITY APPLN. INFO.:			PL 2003-361347 A	20030718
			WO 2004-EP51520 W	20040716

OTHER SOURCE(S): CASREACT 142:198109

AB A process for the preparation of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine (I) comprising reacting Ph 2-(phenylthio) phenylcarbamate with piperazine and cyclizing the obtained N-[(2-phenylthio)phenyl]-1- piperazinylcarboxamide in a presence of cyclizing agent. I is an intermediate in the synthesis of the antipsychotic drug quetiapine.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:470987 HCAPLUS Full-text

DOCUMENT NUMBER: 141:42905

TITLE: Crystallization process for the preparation of the crystalline polymorphic form I of clopidogrel bisulfate

INVENTOR(S): Piechaczek, Janina; Serafin, Jadwiga; Maruszak, Wioleta; Balicki, Roman; Szelejewski, Wieslaw; Cybulski, Marcin; Maciejewski, Grzegorz; Wysoczynska, Maria; Glice, Magdalena; Korczak, Katarzyna

PATENT ASSIGNEE(S): Anpharm Przedsiebiorstwo Farmaceutyczne S.A., Pol.; et al.

SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048385	A2	20040610	WO 2003-PL130	20031126
WO 2004048385	A3	20040805		
W: AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, HR, HU, IL, IS, JP, KG, KR, KZ, LT, LU, LV, MA, MD, MK, MN, MW, MX, NI, NO, NZ, PT, RO, RU, SE, SK, SY, TJ, TM, TR, UA, US, UZ, YU, ZA				

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

AU 2003285841	A1	20040618	AU 2003-285841		20031126
PRIORITY APPLN. INFO.:			PL 2002-254427	A	20021128
			WO 2003-PL130	W	20031126

AB The crystalline polymorphic form I of clopidogrel bisulfate is prepared by precipitating the salt formed in the neutralization reaction of the optically active base of clopidogrel, Me (S)-(+)-α-(2-chlorophenyl)- 4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate with concentrated sulfuric acid, using a precipitating solvent selected from aliphatic and cyclic ethers and iso-Bu Me ketone. An X-ray diffraction pattern of the title polymorphic compound is presented.

RESULTS FROM REGISTRY, CAPLUS, AND USPATFULL

=> d que stat l46
L22 STR



Page 1-A

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L24 132 SEA FILE=REGISTRY SSS FUL L22
L25 3170 SEA FILE=HCAPLUS ABB=ON L24
L30 1719794 SEA FILE=HCAPLUS ABB=ON (L25 OR ?CRYSTALLIN? OR ?XRAY? OR X(W)RAY?(W)?POWDER?(W)?DIFFRACT? OR CUKA OR ?RADIAT?)
L31 103 SEA FILE=HCAPLUS ABB=ON L25 AND (?CRYSTALLIN? OR ?XRAY? OR X(W)RAY?(W)?POWDER?(W)?DIFFRACT? OR CUKA OR ?RADIAT?)
L34 11 SEA FILE=HCAPLUS ABB=ON L31 AND ?SULFONIC?(W)ACID
L36 11 SEA FILE=HCAPLUS ABB=ON L31 AND (20% OR 20 OR 17.23 OR 17.62 OR 18.72 OR 19.90 OR 20.23 OR 21.25 OR 21.59 OR 22.05 OR 22.44 OR 23.38 OR 23.68 OR 24.48 OR 25.41 OR 26.10 OR 28.39 OR 16.91 OR 17.60 OR 18.69 OR 19.78 OR 20.50 OR 21.60 OR 22.00 OR 22.70 OR 23.07 OR 24.49 OR 26.13 OR 27.25)
L37 18 SEA FILE=HCAPLUS ABB=ON L34 OR L36
L39 1508 SEA FILE=HCAPLUS ABB=ON L30 AND (CUKA OR CUKALPHA)
L40 7 SEA FILE=HCAPLUS ABB=ON L39 AND ?SULFONIC?(W)ACID
L41 25 SEA FILE=HCAPLUS ABB=ON L37 OR L40
L42 23 SEA FILE=HCAPLUS ABB=ON L41 AND (PRD<20060929 OR PD<20060929)

L43 756 SEA FILE=USPATFULL ABB=ON L41 AND (PRD<20060929 OR PD<20060929)
L44 750 SEA FILE=USPATFULL ABB=ON L43 AND (20% OR 20 OR 17.23 OR 17.62 OR 18.72 OR 19.90 OR 20.23 OR 21.25 OR 21.59 OR 22.05 OR 22.44 OR 23.38 OR 23.68 OR 24.48 OR 25.41 OR 26.10 OR 28.39 OR 16.91 OR 17.60 OR 18.69 OR 19.78 OR 20.50 OR 21.60 OR 22.00 OR 22.70 OR 23.07 OR 24.49 OR 26.13 OR 27.25)
L45 28 SEA FILE=USPATFULL ABB=ON L44 AND DISULFONIC?(W)ACID
L46 51 DUP REMOV L42 L45 (0 DUPLICATES REMOVED)

```
=> d ibib abs hitstr 146 1-51

L46  ANSWER 1 OF 51  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:585333  HCAPLUS  Full-text
DOCUMENT NUMBER:          147:16553
TITLE:                    Crystal forms of imatinib mesylate and dosage forms
                          containing them for tumor diagnosis and therapy
INVENTOR(S):              Mutz, Michael
PATENT ASSIGNEE(S):       Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE:                   PCT Int. Appl., 43pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
     WO 2007059963        A1    20070531    WO 2006-EP11240         20061123 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       GB 2005-24061       A  20051125 <--
                                             GB 2005-24062       A  20051125 <--
                                             US 2005-740016P     P  20051128 <--
                                             US 2005-740017P     P  20051128 <--
                                             US 2005-740018P     P  20051128 <--
AB   The invention relates to the F-, G-, H-, I-, and K-crystal forms of the
     methanesulfonic acid addition salt of 4-(4-methylpiperazin- 1-yl-methyl)- N-
     [4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]- benzamide
     (imatinib), certain processes for their preparation, pharmaceutical compns.
     containing these crystal forms, their use in diagnostic methods or for the
     therapeutic treatment of warm-blooded animals, especially humans.  Thus,
     crystalline form F of imatinib mesylate was prepared using benzyl alc. or a
     mixture of benzyl alc. and Et acetate and formulated into tablets. Tablets
     containing 100 mg of imatinib mesylate crystal form F were prepared by a
     direct compression of a mixture containing active ingredient 100 mg,
     crystalline lactose 240 mg, Avicel 80 mg, PVPPXL 20 mg, Aerosil 2 mg, and
     magnesium stearate 5 mg.
IT   220127-57-1, Imatinib mesylate
     RL: DGN (Diagnostic use); PEP (Physical, engineering or chemical process);
     PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC
     (Process); USES (Uses)
        (preparation and oral formulations of crystal forms of imatinib mesylate
for
        tumor diagnosis and therapy)
RN   220127-57-1  HCAPLUS
CN   Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
     pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)  (CA INDEX
```

NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 2 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:227059 HCAPLUS Full-text
DOCUMENT NUMBER: 146:280844
TITLE: Delta and epsilon crystal forms of imatinib mesylate
INVENTOR(S): Mutz, Michael
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023182	A1	20070301	WO 2006-EP65662	20060824 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-711737P P 20050826 <--
US 2005-711738P P 20050826 <--
US 2005-712206P P 20050829 <--

AB The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin- 1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]- benzamide, certain processes for their preparation, pharmaceutical compns. containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical prepns. for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans. Thus, tablet was prepared containing δ-imatinib mesylate 100 mg, crystalline lactose 240 mg, Avicel 80 mg, polyvinylpolypyrrolidone, crosslinked 20 mg, Aerosil 2 mg and magnesium stearate 5 mg.

IT 152459-95-5, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delta and epsilon crystal forms of imatinib mesylate)

RN 152459-95-5 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 220127-57-1, Imatinib mesylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delta and epsilon forms; delta and epsilon crystal forms of imatinib mesylate)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:912007 HCAPLUS Full-text
DOCUMENT NUMBER: 147:263390
TITLE: Method of preparing hydroxyapatite based drug delivery, sustained-release implant for infection and cancer treatment
INVENTOR(S): Luo, Ping
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7pp., Cont.-in-part of U.S. Ser. No. 608,488.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007190102	A1	20070816	US 2004-913689	20040809 <--
US 6767550	B1	20040727	US 2000-608488	20000630 <--
PRIORITY APPLN. INFO.:			US 2000-608488	A2 20000630 <--

AB A bioresorbable material is incorporated with bioactive agents to form an implant used for treatment against hard tissue or soft tissue defects and diseases. Antibiotics or anti-cancer agents are incorporated to treat hard or soft tissue infections or cancers. Sustained release of the bioactive agents or drug mols. may be achieved after implantation at the targeted sites. The dosage of the active agents or mols., the microstructure, morphol., and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy. Various microstructure and the morphologies of the implants are injectable like putty or shaped with multilayers. Thus, implant was prepared from a mixture of hydroxyapatite, β-tricalcium phosphate, and calcium sulfate hemihydrate; bone morphogenetic proteins BMP4 and BMP7 at 1:1 ratio (total protein content about 0.5 wt%) were added to make into injectable putty. The putty was settable in 5 to 20 min in bone void due to osteoporosis. Bone morphogenetic proteins exhibited sustained released out of the matrix.

IT 220127-57-1, Imatinib mesylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of preparing hydroxyapatite based drug delivery, sustained-release implant for infection and cancer treatment)

RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 4 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1330840 HCAPLUS Full-text
DOCUMENT NUMBER: 147:548066
TITLE: Crystalline imatinib mesylate, manufacture thereof, manufacture of amorphous imatinib mesylate, and solid compositions containing crystalline or amorphous imatinib mesylate
INVENTOR(S): Jegorov, Alexandr; Veverka, Miroslav; Aronhime, Judith; Gavenda, Ales; Faustmann, Jiri
PATENT ASSIGNEE(S): Ivax Pharmaceuticals Spoleanosti S. R. O., Czech Rep.
SOURCE: Jpn. Kokai Tokkyo Koho, 76pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007302658	A	20071122	JP 2007-120109	20070427 <--
WO 2007136510	A2	20071129	WO 2007-US10321	20070427 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-796253P P 20060427 <--

US 2006-818916P	P	20060705 <--
US 2006-837420P	P	20060810 <--
US 2006-847631P	P	20060926 <--
US 2006-852349P	P	20061016
US 2006-854221P	P	20061024
US 2006-861825P	P	20061129
US 2007-918178P	P	20070314
US 2007-922034P	P	20070404
US 2007-923440P	P	20070412

AB The invention provides crystalline imatinib mesylate solvates with aliphatic alcs., ethers, nitromethane, or acetic acid, with improved handling property. The characteristics of the crystalline imatinib mesylate in solid phase 13CNMR spectra and XRD patterns, method for production of the crystalline imatinib mesylate, method for production of form-α crystal of imatinib mesylate, method for production of amorphous imatinib mesylate, pharmaceutical compns. containing crystalline or amorphous imatinib mesylate, and method for production of the composition are also disclosed. For example, imatinib base 3 g was dispersed in ethanol 60 mL at 10°, methanesulfonic acid 0.375 mL was added therein, and the dispersion was left at -5° for 3 days for crystallization Tert-Bu Me ether 50 mL was added to the dispersion, and white solid was filtered, washed with petroleum ether, and dried to obtain form-IV crystal of imatinib mesylate.

IT 220127-57-1, Imatinib mesylate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(crystalline imatinib mesylate, manufacture thereof, manufacture of amorphous imatinib mesylate, and solid compns. containing crystalline or amorphous imatinib mesylate)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5P, Imatinib
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline imatinib mesylate, manufacture thereof, manufacture of amorphous imatinib mesylate, and solid compns. containing crystalline or amorphous imatinib mesylate)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 5 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:342177 USPATFULL Full-text
TITLE: Photodefinable low dielectric constant material and method for making and using same
INVENTOR(S): Markley, Thomas John, Blandon, PA, UNITED STATES
Weigel, Scott Jeffrey, Allentown, PA, UNITED STATES
Kretz, Christine Peck, Macungie, PA, UNITED STATES
Braymer, Thomas Albert, Allentown, PA, UNITED STATES
Mac Dougall, James Edward, New Tripoli, PA, UNITED STATES
Petit, Cecilia Anna Paulette, Quakertown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007299176	A1	20071227
APPLICATION INFO.:	US 2006-341334	A1	20060127 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-647884P	20050128 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AIR PRODUCTS AND CHEMICALS, INC., PATENT DEPARTMENT, 7201 HAMILTON BOULEVARD, ALLENTOWN, PA, 181951501, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1684

AB A photodefinable, organosilicate material having a dielectric constant (κ) of 3.5 or below and a method for making and using same, for example, in an electronic device, is described herein. In one aspect, there is provided a composition for preparing a photodefinable material comprising: a silica source capable of being sol-gel processed and having a molar ratio of carbon to silicon within the silica source contained therein of at least 0.5 or greater; a photoactive compound; optionally a solvent; and water provided the composition contains 0.1% by weight or less of an added acid where the acid has a molecular weight of 500 or less.

L46 ANSWER 6 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:335779 USPATFULL Full-text
TITLE: N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
INVENTOR(S): Loiseleur, Olivier, Saint-Louis, FRANCE
Kaufmann, Daniel, Therwil, SWITZERLAND
Abel, Stephan, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Burger, Hans Michael, Allschwil, SWITZERLAND
Meisenbach, Mark, Durmenach, FRANCE
Schmitz, Beat, Allschwil, SWITZERLAND
Sedelmeier, Gottfried, Schallstadt, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007293683	A1	20071220
APPLICATION INFO.:	US 2007-845946	A1	20070828 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-503538, filed on 20 Jan 2005, PENDING A 371 of International Ser. No. WO 2003-EP1188, filed on 6 Feb 2003		

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-2873	20020207	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1-20		
LINE COUNT:	776		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel amides and a process for preparing these amides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5P
(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 7 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:335769 USPATFULL Full-text
TITLE: N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
INVENTOR(S): Loiseleur, Olivier, Saint-Louis, FRANCE
Kaufmann, Daniel, Therwil, SWITZERLAND

Abel, Stephan, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Burger, Hans Michael, Allschwil, SWITZERLAND
Meisenbach, Mark, Durmenach, FRANCE
Schmitz, Beat, Allschwil, SWITZERLAND
Sedelmeier, Gottfried, Schallstadt, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007293673	A1	20071220
APPLICATION INFO.:	US 2007-845924	A1	20070828 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2005-503538, filed on 20 Jan 2005, PENDING A 371 of International Ser. No. WO 2003-EP1188, filed on 6 Feb 2003

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-2873	20020207 <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1-20
LINE COUNT: 826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel amides and a process for preparing these amides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5P
(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 8 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:335768 USPATFULL Full-text
TITLE: N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
INVENTOR(S): Loiseleur, Olivier, Saint-Louis, FRANCE
Kaufmann, Daniel, Therwil, SWITZERLAND
Abel, Stephan, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Burger, Hans Michael, Allschwil, SWITZERLAND
Meisenbach, Mark, Durmenach, FRANCE
Schmitz, Beat, Allschwil, SWITZERLAND
Sedelmeier, Gottfried, Schallstadt, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007293672	A1	20071220
APPLICATION INFO.:	US 2007-845914	A1	20070828 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-503538, filed on 20 Jan 2005, PENDING A 371 of International Ser. No. WO 2003-EP1188, filed on 6 Feb 2003		

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-2873	20020207	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1-20		
LINE COUNT:	815		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel amides and a process for preparing these amides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 152459-95-5P

(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)

RN 152459-95-5 USPATFULL

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 9 OF 51 USPATFULL on STN

ACCESSION NUMBER: 2007:335602 USPATFULL Full-text

TITLE: N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES

INVENTOR(S): Loiseleur, Olivier, Saint-Louis, FRANCE
Kaufmann, Daniel, Therwil, SWITZERLAND
Abel, Stephan, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Burger, Hans Michael, Allschwil, SWITZERLAND
Meisenbach, Mark, Durmenach, FRANCE
Schmitz, Beat, Allschwil, SWITZERLAND
Sedelmeier, Gottfried, Schallstadt, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007293504	A1	20071220
APPLICATION INFO.:	US 2007-845934	A1	20070828 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-503538, filed on 20 Jan 2005, PENDING A 371 of International Ser. No. WO 2003-EP1188, filed on 6 Feb 2003		

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-2873	20020207	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1-20		
LINE COUNT:	824		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel amides and a process for preparing these amides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 152459-95-5P

(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)

RN 152459-95-5 USPATFULL

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 10 OF 51 USPATFULL on STN

ACCESSION NUMBER: 2007:296186 USPATFULL Full-text

TITLE: COMPOSITIONS AND METHODS FOR CONVECTION ENHANCED DELIVERY OF HIGH MOLECULAR WEIGHT NEUROTHERAPEUTICS

INVENTOR(S): Bankiewicz, Krystof S., Oakland, CA, UNITED STATES
Kunwar, Sandeep, Hillsborough, CA, UNITED STATES

PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA, UNITED STATES, 94607 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007259031	A1	20071108	
APPLICATION INFO.:	US 2007-740508	A1	20070426	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2006-795371P	20060426 (60)	<--
	US 2007-900492P	20070209 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JOHN P. O'BANION, O'BANION & RITCHEY LLP, 400 CAPITOL MALL SUITE 1550, SACRAMENTO, CA, 95814, US		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	1749		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1, STI 571
(Gleevac; convection-enhanced local delivery of high mol. weight neurotherapeutics for treatment of CNS disorders)
RN 220127-57-1 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 11 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:291200 USPATFULL Full-text
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)	<--
	US 2006-808905P	20060526 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE,

BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel salts of thieno[2,3- d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2- (piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 12 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:224194 USPATFULL Full-text
TITLE: Uv filters in powder form
INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Beck, Jorn, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Driller, Hansjurgen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007196290	A1	20070823	
APPLICATION INFO.:	US 2005-591531	A1	20050208	(10)
	WO 2005-EP1244		20050208	
			20060901	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2004-102004013320040303		<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 2335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to UV filters in powder form, obtainable by spray-drying or freeze-drying a dispersion comprising UV filters, processes for the preparation of UV filters in powder form, and compositions comprising UV filters in powder form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1, Gleevec
(codrug; preparation of N-arylalkyl-thieno[3,2-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis)
RN 220127-57-1 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 13 OF 51 USPATFULL on STN

ACCESSION NUMBER:	2007:101199 USPATFULL Full-text
TITLE:	CLOPIDOGREL SALT AND POLYMORPHIC FORMS THEREOF
INVENTOR(S):	Lorimer, Keith Richard, West Lafayette, IN, UNITED STATES Ng, Alicia Tee Fuay, West Lafayette, IN, UNITED STATES
PATENT ASSIGNEE(S):	Sanofi-aventis, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007088048	A1	20070419
APPLICATION INFO.:	US 2006-550865	A1	20061019 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2005-US13279, filed on 18 Apr 2005, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-563795P	20040420 (60) <--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, SANOFI-AVENTIS U.S. LLC, 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US
NUMBER OF CLAIMS:	42
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Page(s)
LINE COUNT:	608

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methyl(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate or a polymorphic form and/or a hydrate and/or a solvate thereof, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 14 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2007:4656 USPATFULL Full-text
TITLE: Curable resin composition, electrophotographic photoreceptor, process cartridge, and image-forming apparatus
INVENTOR(S): Yamada, Wataru, Kanagawa, JAPAN
Nukada, Katsumi, Kanagawa, JAPAN
Iwasaki, Masahiro, Kanagawa, JAPAN
Yao, Kenji, Kanagawa, JAPAN
PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007003850	A1	20070104	
APPLICATION INFO.:	US 2006-444483	A1	20060601	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 2005-185378	20050624	<--
	JP 2005-373310	20051226	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OLIFF & BERRIDGE, PLC, P.O. BOX 19928, ALEXANDRIA, VA, 22320, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A curable resin composition for use as a constituting material of an electrophotographic photoreceptor, comprises: a phenolic resin; a charge transportable material having a reactive functional group; and at least one of an organic sulfonic acid and its derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 15 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:496044 HCAPLUS Full-text
DOCUMENT NUMBER: 144:495400
TITLE: Polymorphic forms of imatinib mesylate
INVENTOR(S): Kompella, Amala Kishan; Rao, Adibhatla Kali Satya Bhujanga; Podili, Khadgapathi; Chowdary, Nannapaneni Venkaiah
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006054314	A1	20060526	WO 2005-IN273	20050811 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

IN 2004CH01206 A 20061110 IN 2004-CH1206 20041117

PRIORITY APPLN. INFO.: IN 2004-CH1206 A 20041117 <--

AB The present invention relates to novel crystalline polymorphic Form I & Form II of imatinib mesylate and methods for their preparation The Form I is prepared by slurrying imatinib mesylate α2 or β polymorphic Form in chloroform and water with heating and distilling off water followed by filtration. Form II is prepared by lyophilizing an aqueous solution of polymorph α2 or β. The invention also relates to pharmaceutical composition containing the new Forms useful for the treatment of chronic myelogenous leukemia and accelerated stress conditions for the treatment of chronic myelogenous leukemia and accelerated stress conditions.

IT 220127-57-1P, Imatinib mesylate

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (polymorphic forms of imatinib mesylate)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: RCT (Reactant); RACT (Reactant or reagent)
(polymorphic forms of imatinib mesylate)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 16 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:209778 HCAPLUS Full-text
DOCUMENT NUMBER: 144:280587
TITLE: Process for the preparation of imatinib mesylate stable crystalline form
INVENTOR(S): Pathi, Srinivas Laxminarayan; Puppala, Ravikumar; Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramchandra
PATENT ASSIGNEE(S): Cipla Limited, India; Wain, Christopher Paul
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006024863	A1	20060309	WO 2005-GB3392	20050902 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2004MU00951	A	20050624	IN 2004-MU951	20040902 <--
TR 200701870	T1	20070521	TR 2007-1870	20050902 <--
KR 2007063524	A	20070619	KR 2007-707299	20070330 <--
US 2007265288	A1	20071115	US 2007-574642	20070523 <--
PRIORITY APPLN. INFO.:			IN 2004-MU951 A	20040902 <--
			WO 2005-GB3392 W	20050902 <--

GI



I

AB The invention relates to a stable, non hygroscopic alpha crystalline form of methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin- 2-ylamino]phenyl]benzamide (imatinib mesylate, I). A process for the preparation of the crystalline form is also described. Thus, 100 g imatinib was added to 1500 mL iso-Pr alc,. 20 g MeSO3H added, refluxed for 2 h, and cooled to yield 110 g imatinib mesylate α-form.

IT 220127-57-1P, Imatinib mesylate
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of imatinib mesylate stable crystalline form for treatment of leukemia and gastrointestinal stromal tumors)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of imatinib mesylate stable crystalline form for treatment of leukemia and gastrointestinal stromal tumors)

RN 152459-95-5 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 17 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1039160 HCAPLUS Full-text
DOCUMENT NUMBER: 145:383417
TITLE: Preparation of imatinib mesylate α-form
INVENTOR(S): Adin, Itai; Iustain, Carmen; Davidi, Guy; Weisman, Alex; Bentolila, Moshe; Meyer, Elazar; Kaspi, Joseph
PATENT ASSIGNEE(S): Chemagis Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006223816	A1	20061005	US 2006-429731	20060508
DE 102007021043	A1	20071122	DE 2007-102007021043	20070504 <--
FR 2900655	A1	20071109	FR 2007-3276	20070507 <--
PRIORITY APPLN. INFO.:			US 2006-429731 A	20060508 <--

AB Provided is a process for preparing crystalline imatinib mesylate in substantially pure α-form, which preferably includes crystallizing imatinib mesylate from an organic solvent containing imatinib and methanesulfonic acid, and seed crystals of imatinib mesylate α-form, wherein the seed crystals are added before imatinib mesylate begins to precipitate from the mixture Also provided are stable, free-flowing imatinib mesylate crystals in substantially pure α-form, and a pharmaceutical composition containing the stable, free-flowing imatinib mesylate crystals.

IT 220127-57-1P, Imatinib mesylate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imatinib mesylate α-form)

RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of imatinib mesylate α-form)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 18 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2006:214748 USPATFULL Full-text
TITLE: Dyes for anisotropic dye films, dye compositions for anisotropic dye films, anisotropic dye films and polarizing elements
INVENTOR(S): Yoneyama, Tomio, Yokohama-shi, JAPAN
Hasegawa, Ryuichi, Yokohama-shi, JAPAN
Sano, Hideo, Yokohama-shi, JAPAN
Oizumi, Junichi, Yokohama-shi, JAPAN
Nishimura, Masaaki, Yokohama-shi, JAPAN
Kadowaki, Masami, Yokohama-shi, JAPAN
PATENT ASSIGNEE(S): MITSUBISHI CHEMICAL CORPORATION, Minato-ku, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006182902	A1	20060817	<--
APPLICATION INFO.:	US 2006-403982	A1	20060414 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2004-JP15450, filed on 13 Oct 2004, UNKNOWN

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 2003-378399	20031107	<--
	JP 2004-234415	20040811	<--
	JP 2003-353832	20031014	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An anisotropic dye film having high dichromatic properties is provided. An anisotropic dye film wherein the period d attributable to molecular stacking is at most 3.445 Å, and the column length L thereof is at least 105 Å. The anisotropic dye film preferably has a degree of orientation of the molecular stacking axes of at least 85% and a film thickness of at most 30 μm, and is formed by a wet film-forming method. Since it has a molecular alignment suitable to develop a dichroic ratio, it provides high dichromatic properties. A polarizing element having this anisotropic dye film is excellent in heat resistance, light fastness and polarizing performance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 19 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2006:168067 USPATFULL Full-text
TITLE: N-phenyl-2-pyrimidine-amine derivatives
INVENTOR(S): Loiseleur, Olivier, Saint-Louis, SWITZERLAND
Kaufmann, Daniel, Therwil, SWITZERLAND
Abel, Stephan, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Burger, Hans Michael, Allschwil, SWITZERLAND
Meisenbach, Mark, Durmenach, GERMANY, FEDERAL REPUBLIC OF
Schmitz, Beat, Allschwil, SWITZERLAND
Sedelmeier, Gottfried, Schallstadt, SWITZERLAND

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 2006142580	A1	20060629		<--
APPLICATION INFO.:	US 2003-503538	A1	20030206	(10)	
	WO 2003-EP1188		20030206		
			20050120	PCT 371 date	

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-2873	20020207	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel amides and a process for preparing these amides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5P
(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 20 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:228482 HCAPLUS Full-text
DOCUMENT NUMBER: 144:324374
TITLE: Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and γ-irradiation on viability of neuroblastoma cells
AUTHOR(S): Roessler, Jochen; Zambrzycka, Izabella; Lagodny, Jeanette; Kontny, Udo; Niemeyer, Charlotte Marie
CORPORATE SOURCE: Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, Germany
SOURCE: Biochemical and Biophysical Research Communications (2006), 342(4), 1405-1412
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Neuroblastoma (NB) expresses the tyrosine kinase receptors c-Kit, PDGFR-α and -β-targets for STI-571. We investigated a possible combination therapy of STI-571 with retinoic acid (RA) and γ-irradiation on NB cell viability in vitro. Expression of tyrosine kinase receptors and their ligands was examined in 6 NB cell lines by RT-PCR and FACS. The effect on cell viability was determined by MTT assay. Cell viability of all 6 NB cell lines was significantly inhibited after treatment with 20 μM STI-571 for 72 h, two cell lines responding already to 10 μM. Cell lines responded irresp. of their mRNA status or cell surface expression of c-Kit, PDGFR-α and -β. Co-incubation with 9-cis RA sensitized cells to the inhibitory effects of STI-571. However, pre-treatment with 9-cis RA resulted in resistance of NB cell lines to STI-571 and γ-irradiation Treatment of NB with STI-571 in combination with 9-cis RA might be a therapeutic strategy for patients in consolidation therapy who have completed γ-irradiation therapy.
IT 220127-57-1, STI-571
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of STI-571 (imatinib mesylate) in combination with retinoic acid and γ-irradiation on viability of neuroblastoma cells)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 21 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:367973 HCAPLUS Full-text
DOCUMENT NUMBER: 145:289772
TITLE: Female adnexal tumor of probable wolffian origin: morphological, immunohistochemical, and ultrastructural study with c-kit gene analysis
AUTHOR(S): Harada, Oi; Ota, Hiroyoshi; Takagi, Kimiyo; Matsuura, Hiroyuki; Hidaka, Eiko; Nakayama, Jun
CORPORATE SOURCE: Department of Pathology, Shinshu University School of Medicine, Iiyama, Japan
SOURCE: Pathology International (2006), 56(2), 95-100
CODEN: PITEES; ISSN: 1320-5463
PUBLISHER: Blackwell Publishing Asia Pty Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Female adnexal tumors of probable wolffian origin (FATWO) are rare neoplasms believed to originate from mesonephric (wolffian) remnants. Rarity and variable location of FATWO make the diagnosis difficult. Although most cases follow a benign clin. course, approx. 10% of them either recur or metastasize and are thought to be resistant to chemoradiation therapy. In 2004, imatinib therapy, a tyrosine kinase inhibitor known to be effective against gastrointestinal stromal tumors, was reported to be effective also in a case of KIT-pos. FATWO. However, c-kit gene mutations in FATWO have never been studied. Herein is reported the case of a 50-yr-old Japanese woman with FATWO arising in the right paratubal site. The tumor had typical characteristics of FATWO in both morphol. and immunohistochem. KIT protein was diffusely and weakly expressed, but DNA anal. revealed no mutational change in exon 9 or 11

of the c-kit gene. It is believed that accumulation of such genetic data of FATWO are essential from a therapeutic standpoint, although the present case had no mutation. In addition, the cytol. features of this rare tumor are presented, which have not been described previously.

IT 152459-95-5, Imatinib
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calretinin protein was expressed in tumor cells of Japanese woman with female adnexal tumor of probable wolffian origin)

RN 152459-95-5 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 22 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1106857 HCAPLUS Full-text
DOCUMENT NUMBER: 143:392946
TITLE: Preparation of crystalline methanesulfonic acid addition salts of imatinib
INVENTOR(S): Szczepek, Wojciech; Samson-Lazinska, Dorota; Zagrodzki, Bogdan; Glice, Magdalena; Maruszak, Wioleta; Korczak, Kataryzna; Modzelewski, Ryszard; Lawecka, Marta; Kaczmarek, Lukasz; Szelejewski, Wieslaw; Fraczek, Urszula; Cmoch, Piotr
PATENT ASSIGNEE(S): Instytut Farmaceutyczny, Pol.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095379	A2	20051013	WO 2005-PL24	20050402 <--
WO 2005095379	A3	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1742933	A2	20070117	EP 2005-731354	20050402 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,				

HR, LV, MK, YU

US 2007197545 A1 20070823 US 2006-599461 20060929 <--

PRIORITY APPLN. INFO.: PL 2004-366885 A 20040402 <--

PL 2005-374074 A 20050401 <--

WO 2005-PL24 W 20050402 <--

AB The invention relates to the methanesulfonic acid addition salts of imatinib and to the processes for their preparation In particular, the invention relates to the process for the preparation of imatinib methanesulfonate α-crystal form. Furthermore, the invention is directed to a novel acid addition salt of imatinib with 2 mols. of methanesulfonic acid and the polymorphic forms thereof as well as their pharmaceutical compns. The suspension of imatinib in anhydrous EtOH was heated to 75°, and methanesulfonic acid was slowly added dropwise. EtOAc was added and the mixture was cooled to 30°, while being stirred. The seeds of α-crystal form were added and then the mixture was cooled and stirred at 13-20.degree. for 4 h. The crystals were filtered off, and dried to obtain α-crystal form of imatinib mesylate yield: 65.0%.

IT 866527-60-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of crystalline methanesulfonic acid addition salts of imatinib)

RN 866527-60-8 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S

IT 220127-57-1P, IMatinib mesylate

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline methanesulfonic acid addition salts of imatinib)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline methanesulfonic acid addition salts of imatinib)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 23 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:902882 HCAPLUS Full-text
DOCUMENT NUMBER: 143:235468
TITLE: Novel polymorphic form of imatinib mesylate and a process for its preparation
INVENTOR(S): Amala, Kompella; Srinivasa Rao, Thungathurthi; Adibhatla Kali Satya, Bhujanga Rao; Rachakonda, Sreenivas; Venkaiah Chowdary, Nannapaneni; Podili, Khadgapathi
PATENT ASSIGNEE(S): Natco Pharma Limited, India

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077933	A1	20050825	WO 2004-IN352	20041116 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2004CH00105	A	20070302	IN 2004-CH105	20040211
IN 2004CH00706	A	20060623	IN 2004-CH706	20040720 <--
IN 2004CH00712	A	20070914	IN 2004-CH712	20040721 <--
CA 2555804	A1	20050825	CA 2004-2555804	20041116 <--
EP 1720853	A1	20061115	EP 2004-806748	20041116 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: IN 2004-CH105 A 20040211 <--
WO 2004-IN352 W 20041116 <--

AB This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as α2 Form, which is stable at room temperature and even at higher temps. up to 120 °C and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the novel stable α2 form of Imatinib mesylate and other usually employed excipients, useful in the treatment of Chronic Myelogenous Leukemia (CML). This new α2 Form of imatinib mesylate is prepared by slurrying Imatinib base in isopropanol at room temperature followed by addition of methane sulfonic acid and maintaining 50-60 °C followed by filtration. This invention also discloses another process for the preparation of the novel, stable α2 cryst . form of Imatinib Mesylate by the conversion of Imatinib mesylate β-polymorphic modification by suspending it in water and organic solvents, distilling off water azeotropically, cooling and filtering to obtain the α2 crystal form.

IT 220127-57-1P, Imatinib mesylate
RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(novel polymorphic form of imatinib mesylate and a process for its preparation)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel polymorphic form of imatinib mesylate and a process for its preparation)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 24 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:99470 HCAPLUS Full-text
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722 <--
WO 2005009961	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004259760	A1	20050203	AU 2004-259760	20040722 <--
CA 2532865	A1	20050203	CA 2004-2532865	20040722 <--
US 2005038080	A1	20050217	US 2004-895985	20040722 <--
EP 1663978	A2	20060607	EP 2004-786091	20040722 <--
EP 1663978	B1	20071128		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

BR 2004012219	A	20060822	BR 2004-12219	20040722 <--
CN 1856469	A	20061101	CN 2004-80021091	20040722 <--
JP 2006528196	T	20061214	JP 2006-521221	20040722 <--
MX 2006PA00860	A	20060720	MX 2006-PA860	20060123 <--
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123 <--
NO 20060000870	A	20060407	NO 2006-870	20060222 <--
PRIORITY APPLN. INFO.:			US 2003-489102P P	20030723 <--
			US 2004-540326P P	20040202 <--
			WO 2004-US23500 W	20040722 <--

OTHER SOURCE(S): CASREACT 142:197889

GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

IT 220127-57-1, STI-571

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX

NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 25 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2005:287509 USPATFULL Full-text
TITLE: Novel compounds
INVENTOR(S): Fish, Paul Vincent, Sandwich, UNITED KINGDOM
MacKenny, Malcolm Christian, Sandwich, UNITED KINGDOM
Stobie, Alan, Sandwich, UNITED KINGDOM
Wakenhut, Florian, Sandwich, UNITED KINGDOM
Whitlock, Gavin Alistair, Sandwich, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005250775	A1	20051110	<--
APPLICATION INFO.:	US 2005-117896	A1	20050428 (11)	

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2004-9744	20040430	<--
	US 2004-576337P	20040602 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 4565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compounds of Formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and n have any of the values defined in the

specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 26 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2005:171786 USPATFULL Full-text
TITLE: IAP nucleobase oligomers and oligomeric complexes and uses thereof
INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005148535	A1	20050707	<--
APPLICATION INFO.:	US 2004-975974	A1	20041028 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-516192P	20031030 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 3022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5, Imatinib
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 27 OF 51 USPATFULL on STN

ACCESSION NUMBER: 2005:150785 USPATFULL Full-text
TITLE: Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005129696	A1	20050616	<--
APPLICATION INFO.:	US 2003-642065	A1	20030815 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1D, STI571, immunoconjugates
(cancer treatment methods using selected immunoconjugates containing antibodies that bind phosphatidylserines and chemotherapeutic agents)
RN 220127-57-1 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 28 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2005:138567 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of proliferative diseases
INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
Durkin, Jon P., Montreal, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005119217	A1	20050602	<--
APPLICATION INFO.:	US 2004-975790	A1	20041028 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-516263P	20031030 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 5896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods, compositions, and kits for treating a patient having a proliferative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5, Imatinib
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 29 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2005:36945 USPATFULL Full-text
TITLE: Combined cancer treatment methods using selected antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005031620	A1	20050210	<--
APPLICATION INFO.:	US 2003-642058	A1	20030815 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1, STI571
(aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
RN 220127-57-1 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 30 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2005:3839 USPATFULL Full-text
TITLE: Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005002941	A1	20050106	<--
APPLICATION INFO.:	US 2003-642116	A1	20030815 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1, STI571
(secondary antitumor agent; antibodies specific to aminophospholipid and immunoconjugates for diagnosis and treatment of cancer and viral infection)
RN 220127-57-1 USPATFULL

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 31 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:277292 HCAPLUS Full-text
DOCUMENT NUMBER: 142:441624
TITLE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
AUTHOR(S): Abdollahi, Amir; Li, Minglun; Ping, Gong; Plathow, Christian; Domhan, Sophie; Kiessling, Fabian; Lee, Leslie B.; McMahon, Gerald; Groene, Hermann-Josef; Lipson, Kenneth E.; Huber, Peter E.
CORPORATE SOURCE: Department of Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
SOURCE: Journal of Experimental Medicine (2005), 201(6), 925-935
CODEN: JEMEAV; ISSN: 0022-1007
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pulmonary fibrosis is the consequence of a variety of diseases with no satisfying treatment option. Therapy-induced fibrosis also limits the efficacy of chemotherapy and radiotherapy in numerous cancers. Here, the authors studied the potential of platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitors (RTKIs) to attenuate radiation -induced pulmonary fibrosis. Thoraces of C57BL/6 mice were irradiated (20 Gy), and mice were treated with 3 distinct PDGF RTKIs (SU9518, SU11657, or Imatinib). Irradiation was found to induce severe lung fibrosis resulting in dramatically reduced mouse survival. Treatment with PDGF RTKIs markedly attenuated the development of pulmonary fibrosis in excellent correlation with clin.,

histol., and computed tomog. results. Importantly, RTKIs also prolonged the life span of irradiated mice. The authors found that radiation up-regulated expression of PDGF (A-D) isoforms leading to phosphorylation of PDGF receptor, which was strongly inhibited by RTKIs. The authors' findings suggest a pivotal role of PDGF signaling in the pathogenesis of pulmonary fibrosis and indicate that inhibition of fibrogenesis, rather than inflammation, is critical to antifibrotic treatment. This study points the way to a potential new approach for treating idiopathic or therapy-related forms of lung fibrosis.

IT 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of platelet-derived growth factor signaling attenuates radiation-induced pulmonary fibrosis)

RN 152459-95-5 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 32 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1059344 HCAPLUS Full-text
DOCUMENT NUMBER: 142:43785
TITLE: Novel polymorphs of imatinib mesylate
INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari; Subash Chander Reddy, Kesireddy
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106326	A1	20041209	WO 2003-IN206	20030602 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 194051	A1	20040828	IN 2003-CN851	20030602 <--
IN 2003CN00851	A	20050422		
AU 2003237596	A1	20050121	AU 2003-237596	20030602 <--

TR 200504337	T1	20061221	TR 2005-4337	20030602 <--
IN 2004CH00500	A	20060602	IN 2004-CH500	20040602 <--
US 2005234069	A1	20051020	US 2004-518213	20041216 <--
US 7300938	B2	20071127		

PRIORITY APPLN. INFO.: WO 2003-IN206 W 20030602 <--

AB Polymorphs of imatinib mesylate, and processes for their preparation and pharmaceutical compns. containing them is claimed. Imatinib mesylate is prepared from imatinib free base by dissolved in a chlorinated solvent and reacting with methanesulfonic acid. The cryst . form of imatinib mesylate characterized by an X-ray powder diffraction spectrum. Imatinib mesylate hydrate is prepared by dissolving imatinib mesylate in a mixture of a suitable solvent and water and removing the solvents from the solution An example describes the preparation of imatinib mesylate by dissolving imatinib free base (5.0 gm) chloroform (50 mL) at room temperature and then methanesulfonic acid (0.75 mL) is added. The contents are stirred for 5 h at room temperature and separated crystals are filtered and dried to give 5.0 gm of imatinib mesylate form H1.

IT 220127-57-1P, Imatinib mesylate
RL: IMF (Industrial manufacture); PRP (Properties); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(polymorphs of imatinib mesylate and preparation of imatinib mesylate hydrates and pharmaceutical compns. containing them)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 220127-57-1DP, Imatinib mesylate, hydrate
RL: IMF (Industrial manufacture); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphs of imatinib mesylate and preparation of imatinib mesylate hydrates and pharmaceutical compns. containing them)

RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 152459-95-5, Imatinib
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(polymorphs of imatinib mesylate and preparation of imatinib mesylate hydrates and pharmaceutical comps. containing them)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 33 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2004:279855 USPATFULL Full-text
TITLE: Selected immunoconjugates for binding to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004219155	A1	20041104	<--
APPLICATION INFO.:	US 2003-642099	A1	20030815 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 1100, 10333 Richmond, Houston, TX, 77042
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220127-57-1, STI571
(aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
RN 220127-57-1 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L46 ANSWER 34 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:607111 HCAPLUS Full-text
DOCUMENT NUMBER: 141:274709
TITLE: Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation
AUTHOR(S): Deng, Xinzhu; Hofmann, E. Randal; Villanueva, Alberto; Hobert, Oliver; Capodieci, Paola; Veach, Darren R.; Yin, Xianglei; Campodonico, Luis; Glekas, Athanasios; Cordon-Cardo, Carlos; Clarkson, Bayard; Bornmann, William G.; Fuks, Zvi; Hengartner, Michael O.; Kolesnick, Richard
CORPORATE SOURCE: Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
SOURCE: Nature Genetics (2004), 36(8), 906-912
CODEN: NGENEC; ISSN: 1061-4036
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB C-Abl, a conserved nonreceptor tyrosine kinase, integrates genotoxic stress responses, acting as a transducer of both pro- and antiapoptotic effector pathways. Nuclear c-Abl seems to interact with the p53 homolog p73 to elicit apoptosis. Although several observations suggest that cytoplasmic localization of c-Abl is required for antiapoptotic function, the signals that mediate its antiapoptotic effect are largely unknown. Here we show that worms carrying an abl-1 deletion allele, abl-1(ok171), are specifically hypersensitive to radiation-induced apoptosis in the C. elegans germ line. Our findings delineate an apoptotic pathway antagonized by ABL-1, which requires sequentially the cell cycle checkpoint genes clk-2, hus-1, and mrt-2; the C. elegans p53 homolog, cep-1; and the genes encoding the components of the conserved apoptotic machinery, ced-3, ced-9, and egl-1. ABL-1 does not antagonize germline apoptosis induced by the DNA-alkylating agent ethylnitrosourea. Furthermore, worms treated with the c-Abl inhibitor STI-571 (Gleevec; used in human cancer therapy), 2 newly synthesized STI-571 variants, or PD166326 had a phenotype similar to that generated by abl-1(ok171). These studies indicate that ABL-1 distinguishes proapoptotic signals triggered by 2 different DNA-damaging agents and suggest that C. elegans might provide tissue models for development of anticancer drugs.

IT 220127-57-1, STI-571
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nematode ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 35 OF 51 USPATFULL on STN
ACCESSION NUMBER: 2003:181510 USPATFULL Full-text
TITLE: Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
INVENTOR(S): Gambacorti-Passerini, Carlo, Monza, ITALY
Lecoutre, Philipp, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125343	A1	20030703	<--
APPLICATION INFO.:	US 2002-169035	A1	20021007 (10)	
	WO 2000-EP31361		20001222	

	NUMBER	DATE	
PRIORITY INFORMATION:	IT 1999-MI2711	19991227	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to combinations of an abl-, PDGF-Receptor-and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to α.sub.1-acidic glycoprotein (AGP), as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to inhibition of abl-, PDGF-Receptor- and/or Kit-receptor tyrosine kinase. In particular, the invention relates to products or combinations comprising and abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to AGP, either in fixed combination

or for chronologically staggered or simultaneous administration, and the combined used of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, especially those that can be treated by inhibition of abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 152459-95-5, cgp57148
(antitumor combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to α1-acidic glycoprotein)
RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L46 ANSWER 36 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:77563 HCAPLUS Full-text
DOCUMENT NUMBER: 130:158400
TITLE: Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
INVENTOR(S): Zimmermann, Jurg; Sutter, Bertrand; Burger, Hans Michael
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9903854	A1	19990128	WO 1998-EP4427	19980716	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
TW 491845	B	20020621	TW 1998-87111408	19980714	<--
CA 2296604	A1	19990128	CA 1998-2296604	19980716	<--
AU 9889759	A	19990210	AU 1998-89759	19980716	<--
AU 740713	B2	20011115			
EP 998473	A1	20000510	EP 1998-941342	19980716	<--
EP 998473	B1	20031001			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,					

IE, SI, FI, RO

BR 9810920	A	20000815	BR 1998-10920	19980716	<--
TR 200000060	T2	20000921	TR 2000-60	19980716	<--
HU 2000003230	A2	20010628	HU 2000-3230	19980716	<--
HU 2000003230	A3	20020128			
JP 2001510192	T	20010731	JP 2000-503078	19980716	<--
JP 3276359	B2	20020422			
NZ 502295	A	20011221	NZ 1998-502295	19980716	<--
RU 2208012	C2	20030710	RU 2000-102914	19980716	<--
AT 251152	T	20031015	AT 1998-941342	19980716	<--
CN 1134429	B	20040114	CN 1998-807303	19980716	<--
PT 998473	T	20040227	PT 1998-941342	19980716	<--
ES 2209194	T3	20040616	ES 1998-941342	19980716	<--
PL 188348	B1	20050131	PL 1998-338129	19980716	<--
CZ 298531	B6	20071031	CZ 2000-149	19980716	<--
ZA 9806362	A	19990122	ZA 1998-6362	19980717	<--
IN 1998MA01602	A	20050415	IN 1998-MA1602	19980717	<--
NO 2000000227	A	20000117	NO 2000-227	20000117	<--
NO 319486	B1	20050822			
MX 200000620	A	20010131	MX 2000-620	20000117	<--
US 6894051	B1	20050517	US 2000-463097	20000118	<--
HK 1028599	A1	20040430	HK 2000-107150	20001109	<--
US 2002115858	A1	20020822	US 2001-991184	20011116	<--
US 7151106	B2	20061219			
IN 2004CH00799	A	20061006	IN 2004-CH799	20040812	<--
US 2005192284	A1	20050901	US 2005-74399	20050307	<--
NO 2005002755	A	20000117	NO 2005-2755	20050607	<--
IN 2005CH01075	A	20070928	IN 2005-CH1075	20050805	<--
US 2006030568	A1	20060209	US 2005-241266	20050929	<--
IN 2005CH01750	A	20070914	IN 2005-CH1750	20051130	<--
US 2007004746	A1	20070104	US 2006-515997	20060905	<--

PRIORITY APPLN. INFO.:

CH 1997-1764	A	19970718 <--
WO 1998-EP4427	W	19980716 <--
IN 1998-MA1602	A3	19980717 <--
US 2000-463097	A1	20000118 <--
US 2001-991184	A1	20011116 <--
US 2005-241266	A1	20050929 <--

GI



I

AB The invention relates to a new crystalline form of the methanesulfonic acid addition salt of I which may be used, for example, for tumor therapy. I was treated with methanesulfonic acid in MeOH to give the α-crystal form which in MeOH solution is inoculated with a β-crystal form to give the β-variants. Tablets and capsules were prepared containing these crystal forms.

IT 152459-95-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(salt formation of; crystal modification of a N-phenyl-2-pyrimidineamine derivative for pharmaceuticals)
RN 152459-95-5 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 220127-57-1P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(β-form; crystal modification of a N-phenyl-2-pyrimidineamine derivative for pharmaceuticals)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 37 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:681448 HCAPLUS Full-text

DOCUMENT NUMBER: 131:311685
TITLE: Brilliant and glossy mono azo calcium lake pigments and their manufacture
INVENTOR(S): Yo, Iemasa; Yasui, Kengo; Sunouchi, Shinichi; Ui, Kumiko
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11293138	A	19991026	JP 1998-98974	19980410 <--
PRIORITY APPLN. INFO.:			JP 1998-98974	19980410 <--

AB The pigments have strong intensity at X-ray diffraction angle (20±0.2°; CuKα) 4.6° and weak intensity at 9.2, 14.0, 17.9, 22.4, 23.4, 24.7 and 25.7°, and are prepared by coupling β-naphthol with a diazotized mixture of 40-60 mol% 2-chloro-4-aminotoluene-5-sulfonic acid and 60-40 mol% 2-chloro-5-aminoethylbenzene-4-sulfonic acid, laking the resulting pigment with a Ca source at 70-90° and heating at 70-95° for 0.5-5 h.

L46 ANSWER 38 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:498076 HCAPLUS Full-text
DOCUMENT NUMBER: 129:204135
TITLE: Mono azo lake pigments free from toxic barium and manufacture thereof with high brightness and gloss.
INVENTOR(S): Yadotani, Masao; Sunouchi, Shinichi; Ui, Kumiko
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10204313	A	19980804	JP 1997-6459	19970117 <--
PRIORITY APPLN. INFO.:			JP 1997-6459	19970117 <--

AB The title pigments have X-ray diffractograms showing strong diffraction intensity at diffraction angle (20±0.2°; CuK. alpha.) 4.8° and 24.9° and weak intensity at 9.7°, 14.5°, 18.1°, and 25.8°, and the dyes used for laking with Ca are from 1-amino-4-chloro-5-methylbenzene-2- sulfonic acid, 1-amino-4-methyl-5-chlorobenzene-2- sulfonic acid, and β-naphthol.

L46 ANSWER 39 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:204484 HCAPLUS Full-text
DOCUMENT NUMBER: 126:200661
TITLE: Water-insoluble red monoazo dye, manufacture thereof, and dyeing of polyester fibers with the same
INVENTOR(S): Himeno, Kyoshi; Ando, Hideyuki
PATENT ASSIGNEE(S): Daisutaa Japan Kk, Japan; Dystar Japan Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09003352	A	19970107	JP 1995-177998	19950622 <--
JP 3746813	B2	20060215		

PRIORITY APPLN. INFO.: JP 1995-177998 19950622 <--
GI



I

AB The monoazo dye I has relatively strong peaks at diffraction angles (2θ) 5.2, 12.0, and 17.0° and medium peaks at 20.0, 23.0, 24.1, 25.2, and 28.1° in x-ray diffraction (CuK. alpha.). Diazotizing 8.8 g 2-amino-6-nitrobenzothiazole in H3PO4/H2SO4/nitrosylsulfuric acid, adding the diazotized solution dropwise to a solution containing 7.2 g N-ethyl-N-cyanoethylaniline, and treating the mixture gave 14.6 g I. Polyester fibers (100 g) were dyed red uniformly by immersion into an aqueous solution containing I 0.2, naphthalenesulfonic acid-HCHO condensation product 0.2, and higher alc. sulfate ester 0.2 g at 135° for 30 min. The dye showed high dispersion stability under severe dyeing conditions and gave a dyed product with good color fastness to light and rubbing.

L46 ANSWER 40 OF 51 USPATFULL on STN
ACCESSION NUMBER: 96:53429 USPATFULL Full-text
TITLE: Methine compounds
INVENTOR(S): Hioki, Takanori, Kanagawa, Japan
Ikeda, Tadashi, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5527914		19960618	<--
APPLICATION INFO.:	US 1994-238023		19940503 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1992-909654, filed on 7 Jul 1992, now abandoned which is a division of Ser. No. US 1991-656524, filed on 19 Feb 1991, now patented, Pat. No. US 5166047

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1990-43789	19900223	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert

LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 2743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methine compounds are described, which can be represented by general formula [Ic]: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 41 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:87783 HCAPLUS Full-text
DOCUMENT NUMBER: 124:178818
TITLE: A water-insoluble blue monoazo dye and dyeing polyester fibers therewith with
INVENTOR(S): Himeno, Kyoshi; Mori, Takashi
PATENT ASSIGNEE(S): Hoechst Mitsubishi Kasei, Japan; Dystar Japan Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07304990	A	19951121	JP 1994-124432	19940513 <--
JP 3638306	B2	20050413		

PRIORITY APPLN. INFO.: JP 1994-124432 19940513 <--
GI



I

AB The dye I having crystal structure characterized by an x-ray diffraction pattern (CuKα) exhibiting strong peaks at diffraction angle (2θ) .apprx.5.0, 22.8, 23.5, 24.9, and .apprx.25.1°, resp., and medium peaks at .apprx.6.5, 8.0, 11.3, 14.4, 17.0, 18.0, and .apprx.19.6°, resp., and is useful for dyeing polyester fibers at high temps. with good leveling. Diazotizing 5.6 g 6-chloro-2,4-dinitroaniline in 98% H2SO4 containing nitrosylsulfuric and coupling the resulting product with 3-(N,N-diethylamino)-4- methoxyacetanilide gave 10 g amorphous I, which was dispersed in H2O and stirred at 90-95° for 3 h to give crystallized I. A fabric of polyester fibers was dyed at 135° for 30 min in an aqueous dispersion containing crystalline I, naphthalenesulfonic acid-HCHO condensate, and a higher alc. sulfate, soaped, washed, and dried to give a blue fabric exhibiting good leveling, lightfastness rating 5, and crocking fastness rating 5.

L46 ANSWER 42 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:87782 HCAPLUS Full-text

DOCUMENT NUMBER: 124:234856
TITLE: A water-insoluble blue monoazo dye and dyeing polyester fibers therewith with good leveling and colorfastness
INVENTOR(S): Himeno, Kyoshi; Hibara, Toshio; Shimizu, Yukiharu
PATENT ASSIGNEE(S): Hoechst Mitsubishi Kasei, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07304989	A	19951121	JP 1994-120561	19940510 <--

PRIORITY APPLN. INFO.: JP 1994-120561 19940510 <--
GI



I

AB The dye I having crystal structure characterized by an x-ray diffraction pattern (CuKα) showing strong peaks at diffraction angle (2θ) .apprx.7.8, 12.7, and 26.4°, resp., and medium peaks at .apprx.9.2, 13.7, 16.0, 19.1, 22.6, 27.8, and 29.0°, resp., and is useful for dyeing polyester fibers at high temps. with good leveling. Diazotizing 8.45 g 2-amino-5-nitro-3-cyanothiophene in 98% H2SO4 containing nitrosylsulfuric acid and coupling the resulting product with 10.3 g N,N-diethylamino-m-acetanilide gave a wet cake of amorphous I, which was heated to 80° and kept 5 h to give crystallized I. A fabric of polyester fibers was dyed at 135° for 30 min in an aqueous dispersion containing crystalline I, naphthalenesulfonic acid-HCHO condensate, and a higher alc. sulfate, soaped, washed, and dried to give a blue fabric exhibiting good leveling and lightfastness rating 5 and and crocking fastness rating 5.

L46 ANSWER 43 OF 51 USPATFULL on STN
ACCESSION NUMBER: 95:60257 USPATFULL Full-text
TITLE: Silver halide emulsion
INVENTOR(S): Hioki, Takanori, Kanagawa, Japan
Ikeda, Tadashi, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5429920		19950704	<--
APPLICATION INFO.:	US 1993-108253		19930819	(8)
DISCLAIMER DATE:	20100629			
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-658714, filed on 21 Feb 1991, now abandoned			

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1990-41998	19900222	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chea, Thorl
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A silver halide emulsion containing at least one member of methine dyes represented by the following general formula (I): ##STR1## wherein MET represents an atomic group having a methine dye structure; Q represents a bivalent bonding group comprising at least one atom of carbon atom, nitrogen atom, sulfur atom and oxygen atom or an atomic group having at least one atom of carbon atom, nitrogen atom, sulfur atom and oxygen atom; Ar represents a group which has an aromatic character and derives from a polycyclic compound composed of 8 or more atoms excluding nitrogen atom; l.sub.1 represents 1 or 2; l.sub.2 represents 0 or 1; and l.sub.3 represents 1, 2, 3 or 4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 44 OF 51 USPATFULL on STN
ACCESSION NUMBER: 95:57820 USPATFULL Full-text
TITLE: Synthesized inorganic ion exchange material and detergent composition containing the same
INVENTOR(S): Sakaguchi, Mikio, Wakayama, Japan
Sakamoto, Ichiro, Wakayama, Japan
Kuroda, Mutsumi, Utsunomiya, Japan
Tsumadori, Masaki, Wakayama, Japan
Hasumi, Motomitsu, Wakayama, Japan
Sakamoto, Yuichi, Wakayama, Japan
Akagi, Ryuichi, Wakayami, Japan
Sai, Fumio, Utsunomiya, Japan
PATENT ASSIGNEE(S): Kao Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5427711		19950627	<--
APPLICATION INFO.:	US 1994-246711		19940520	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-997928, filed on 29 Dec 1992, now abandoned			

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1991-359269	19911229	<--
	JP 1991-359271	19911229	<--
	JP 1991-359272	19911229	<--
	JP 1992-297845	19921008	<--
	JP 1992-297846	19921008	<--
	JP 1992-297847	19921008	<--
	JP 1992-297848	19921008	<--
	JP 1992-297849	19921008	<--
	JP 1992-297850	19921008	<--
	JP 1992-297851	19921008	<--
	JP 1992-328417	19921112	<--

JP 1993-179839 19930626 <--
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lieberman, Paul
ASSISTANT EXAMINER: Douyon, Lorna M.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 3426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The synthesized crystalline ion exchange material or a hydrate thereof has a chain structure and a composition represented by the following general formula (A) in an anhydride form:

xM.sub.2 O.ySiO.sub.2.zM'O, (A)

wherein M represents Na and/or K; M' represents Ca and/or Mg; y/x is 0.5 to 2.0; and z/x is 0.005 to 1.0. The chain structure exhibits at least one main scattering peak at 970.+-.20 cm.sup.-1 in Raman spectra. The detergent composition contains the above synthesized inorganic crystalline ion exchange material. The inorganic ion exchange material of the present invention is excellent in both cationic exchange capacity and anti-solubility, making it useful to be used for a water softener and alkalinity regulator in detergents. The detergent composition of the present invention contains an inorganic ion exchange material which has anti-solubility as well as excellent ion exchange capacity and alkaline capacity, thereby offering excellent washing effects and is suitable for the concentration of detergent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 45 OF 51 USPATFULL on STN
ACCESSION NUMBER: 95:3744 USPATFULL Full-text
TITLE: Method for processing a silver halide photographic material using a processing solution having a bleaching ability containing one of an amidine or a bisguanidine compound
INVENTOR(S): Nakamura, Koichi, Kanagawa, Japan
Yabuki, Yoshiharu, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5380626		19950110	<--
APPLICATION INFO.:	US 1993-42800		19930406	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1992-112377	19920406	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bowers, Jr., Charles L.
ASSISTANT EXAMINER: Pasterczyk, J.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1
LINE COUNT: 1999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for forming an image in a silver halide color photographic material comprising a support having thereon at least one light-sensitive silver halide emulsion layer, which comprises imagewise exposing the silver halide color photographic material, color developing the exposed material and then subjecting the developed material to a desilverization treatment, wherein the desilverization treatment is carried out using a processing solution having a bleaching ability and containing at least one of an amidine compound or a bisguanidine compound and a ferric salt of an organic acid, and also a method for processing a silver halide photographic material wherein processing is additionally carried out in the presence of a stilbene fluorescent brightener using a desilverization bath containing at least one of an amidine compound or a bisguanidine compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 46 OF 51 USPATFULL on STN
ACCESSION NUMBER: 94:90927 USPATFULL Full-text
TITLE: Methine compound and silver halide light-sensitive material containing the methine compound
INVENTOR(S): Hioki, Takanori, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5356769		19941018	<--
APPLICATION INFO.:	US 1993-31824		19930316	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1992-4090094	19920317	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Baxter, Janet C.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 2028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methine compounds of formulas (I), (II) and (III) are disclosed: ##STR1## wherein R.sub.3, R.sub.5 and R.sub.5a each represents an alkyl group, an aryl group, or a heterocyclic group, and the remaining symbols are defined in the specification. A silver halide light-sensitive material containing at least one of the methine compounds is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 47 OF 51 USPATFULL on STN
ACCESSION NUMBER: 94:31444 USPATFULL Full-text
TITLE: Photographic developing apparatus
INVENTOR(S): Hayashi, Hiroshi, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 5302995	19940412	<--
APPLICATION INFO.:	US 1992-932545	19920820 (7)	

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1991-233780	19910822	<--
	JP 1992-177765	19920612	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ruthledge, D.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2007

AB A wet photographic processing apparatus adapted for processing an imagewise exposed silver halide photographic material compsiring a support having thereon at least one light-sensitive silver halide emulsion layer, said processing comprising at least developing step followed by at least one of a washing step and a stabilizing step, said apparatus comprising: (i) a developing bath; (ii) at least one set of a plurality of washing baths in cascade connection to form countercurrent and/or a plurality of stabilizing baths in cascade connection to form countercurrent; (iii) means for filtering at least a portion of a washing and/or stabilizing solution drawn from a upstream bath among said plurality of baths, said filtering means including a reverse osmotic membrane apparatus filtering said washing and/or stabilizing solution to produce a filtrate; (iv) means for introducing the filtrate from said reverse osmotic membrane apparatus into a downstream bath among said plurality of baths; and (v) means, provided in said pipe, for shutting-off fluid flow between said upstream bath and said reverse osmotic membrane apparatus. The present apparatus prevents loss of processing solution and contamination of the washing baths upon suspension of operation of the processing apparatus.

L46 ANSWER 48 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1994:674781 HCAPLUS Full-text
DOCUMENT NUMBER:	121:274781
TITLE:	A crystallographic study of heme binding to ferritin
AUTHOR(S):	Precigoux, G.; Yariv, J.; Gallois, B.; Dautant, A.; Courseille, C.; d'Estaintot, B. Langlois
CORPORATE SOURCE:	Laboratoire de Cristallographie et Physique Cristalline, Universite de Bordeaux I, Talence, 33405, Fr.
SOURCE:	Acta Crystallographica, Section D: Biological Crystallography (1994), D50(5), 739-43 CODEN: ABCRE6; ISSN: 0907-4449
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Ferritin, the iron-storage protein, binds porphyrins, metalloprophyrins and the fluorescent dyes, e.g. ANS (8-anilino-1- naphthalenesulfonic acid), similarly to apo-myoglobin. Octahedral crystals of horse-spleen apo-ferritin (HSF; 174 amino acids) complexes prepared by the addition of heme, hematoporphyrin or Sn-protoporphyrin IX to a solution of apo-ferritin crystallize in space group F432 with cell parameter a = 184.0 Å. X-ray crystallog. anal. of single crystals prepared from a mixture containing heme or Sn-protoporphyrin IX shows that the heme-binding sites in these crystals

are occupied by protoporphyrin IX, which is free of metal, rather than by the original metalloporphyrin. The present paper describes the structure of horse spleen apo-ferritin cocrystd. with Sn-protoporphyrin IX. The 6797 reflections up to 2.6 Å resolution used in the refinement were obtained from a data set recorded on a Nicolet/Xentronics area detector with CuKα radiation from a Rigaku RU 200 rotating anode. The final structure comprises 1613 non-H atoms, two Cd atoms and 170 solvent mols. Four residues are described as disordered. The root-mean-square deviations from ideal bond lengths and angles are 0.013 Å and 2.88°, resp. Protoporphyrins are observed in special positions on the two-fold axes of the ferritin mol. with a stoichiometry of 0.4 per subunit.

L46 ANSWER 49 OF 51 USPATFULL on STN
ACCESSION NUMBER: 93:1288 USPATFULL Full-text
TITLE: Method for processing silver halide color photographic materials
INVENTOR(S): Nakamura, Koichi, Kanagawa, Japan
Ohki, Nobutaka, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5176987		19930105	<--
APPLICATION INFO.:	US 1991-776851		19911016 (7)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-558542, filed on 27 Jul 1990, now abandoned			

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1989-196026	19890728	<--
	JP 1990-88825	19900403	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schilling, Richard L.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 2328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for processing an imagewise exposed color photographic material using fast developing time while maintaining stable processing conditions, reduced developer replenishing, and light fastness of developed color images. The method comprises developing a color photographic material containing silver halide grains comprising (i) substantially no silver iodide and (ii) at least about 80 mol % silver chloride with a developer comprising (i) substantially no benzyl alcohol and (ii) a p-phenylenediamine derivative represented by the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each represents an alkyl group having from 1 to 4 carbon atoms and R.sup.2 represents a straight chain or branched alkylene group having 3 or 4 carbon atoms and wherein the developing is for a period of time of less than 30 seconds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 50 OF 51 USPATFULL on STN
ACCESSION NUMBER: 92:92657 USPATFULL Full-text
TITLE: Methine compounds
INVENTOR(S): Hioki, Takanori, Kanagawa, Japan

Ikeda, Tadashi, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co. Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5166047		19921124	<--
APPLICATION INFO.:	US 1991-656524		19910219 (7)	

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1990-43789	19900223	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bowers, Jr., Charles L.
ASSISTANT EXAMINER: Baxter, Janet C.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn Macpeak & Seas
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 2761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Silver halide photographic materials containing methine compounds of general formulas Ia, Ib, Ic, IIa, and IIb are disclosed. The variables are as defined in the present specification. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L46 ANSWER 51 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:467582 HCAPLUS Full-text
DOCUMENT NUMBER: 69:67582
ORIGINAL REFERENCE NO.: 69:12639a,12642a
TITLE: Alkaloids of the Papaveraceae. VIII. The structures of coulteropine and other protopine-type alkaloid acid salts
AUTHOR(S): Stermitz, F. R.; Coomes, R. M.; Harris, D. R.
CORPORATE SOURCE: Colorado State Univ., Fort Collins, CO, USA
SOURCE: Tetrahedron Letters (1968), (36), 3915-20
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB From ir evidence it is clear that acid salts of protopine-type alkaloids cannot be represented by a simple N-protonated structure but that closure of the central 10-membered ring must have occurred. Thus the recently isolated coulterpine (I) must have acid salt structures (II, III) indistinguishable by ir studies. I in C6H6 bubbled through with anhydrous HBr and the amorphous precipitate recrystd. from MeOH-C6H6 yielded I.HBr salt (IV), m. 231-2° in elongated colorless rhomboidal prisms, space group P212121 (orthorhombic), λ 1.5418 A. (CuK. alpha.), a 15.19, b 17.82, c 7.20, Z = 4, d. 1.571 g./cc. The x-ray structure confirmed that suggested by chemical and spectral data and indicated formation of the trans compound II. N.M.R. studies of I in various concns. of CF3CO2H in CDCl3 suggested that under proper conditions an acid salt of I could be isolated in which no ring closure had occurred. Spectra of I or IV in pure CF3CO2H taken immediately showed the presence of the trans compound II but on keeping several hrs. at 20° the spectra then showed the presence of a 2nd component, probably the cis compound III. The results of these studies have some bearing on Perkin's classical efforts to resolve cryptopine by preparation of a bromocamphor sulfonic acid salt.

SEARCH HISTORY

```
=> d his ful

     (FILE 'HOME' ENTERED AT 16:57:40 ON 15 JAN 2008)

     FILE 'HCAPLUS' ENTERED AT 16:57:48 ON 15 JAN 2008
                E SZCZEPEK/AU
                E SZCZEPEK W/AU
L1           48 SEA ABB=ON  ("SZCZEPEK W J"/AU OR "SZCZEPEK WCISLO KATARZYNA"/A
                U OR "SZCZEPEK WOJCIECH"/AU OR "SZCZEPEK WOJCIECH J"/AU)
                E SAMSON-LAZINSKA D/AU
                E LAZINSKA D/AU
                E SAMSON D/AU
L2           13 SEA ABB=ON  "SAMSON D"/AU
                E ZAGRODZKI BOGDAN/AU
L3            7 SEA ABB=ON  ("ZAGRODZKI B"/AU OR "ZAGRODZKI BOGDAN"/AU)
                E GLICE MAGDALENA/AU
L4           21 SEA ABB=ON  ("GLICE M"/AU OR "GLICE M M"/AU OR "GLICE MAGDALENA
                "/AU OR "GLICE MAGDALENA M"/AU)
                E MARUSZAK WIOLETA/AU
L5           17 SEA ABB=ON  ("MARUSZAK W"/AU OR "MARUSZAK WIOLETA"/AU)
                E KORCZAK KATARZYNA/AU
L6            5 SEA ABB=ON  ("KORCZAK KATARYZNA"/AU OR "KORCZAK KATARZYNA"/AU)
                E LAWECKA MARTA/AU
L7            9 SEA ABB=ON  ("LAWECKA M"/AU OR "LAWECKA MARTA"/AU)
                E KACZMAREK LUKASZ/AU
L8          101 SEA ABB=ON  ("KACZMAREK LUDASZ"/AU OR "KACZMAREK LUKASZ"/AU)
                E SZELEJEWSKI WIESLAW/AU
L9          172 SEA ABB=ON  ("SZELEJEWSKI WIELSAW"/AU OR "SZELEJEWSKI WIESDAW"/
                AU OR "SZELEJEWSKI WIESLAW"/AU)
                E FRACZEK URSZULA/AU
L10           3 SEA ABB=ON  "FRACZEK URSZULA"/AU
                E CMOCH PIOTR/AU
L11          23 SEA ABB=ON  ("CMOCH P"/AU OR "CMOCH PIOTR"/AU)
L12           0 SEA ABB=ON  L1 AND L2 AND L3 AND L4 AND L5 AND L6 AND L7 AND
                L8 AND L9 AND L10 AND L11
L13         388 SEA ABB=ON  L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9
                OR L10 OR L11
L14           2 SEA ABB=ON  L13 AND ?METHANESULFONIC ACID?
L15           3 SEA ABB=ON  L13 AND ?CRYSTAL?(W)?POLYMORPH?
L16           5 SEA ABB=ON  L14 OR L15
L17             ANALYZE L16 1-5 CT :      21 TERMS
L18           2 SEA ABB=ON  L13 AND 4(W)?METHYLPIPERAZIN?

     FILE 'REGISTRY' ENTERED AT 17:07:11 ON 15 JAN 2008
L19           1 SEA ABB=ON  139755-83-2/RN

     FILE 'HCAPLUS' ENTERED AT 17:08:16 ON 15 JAN 2008
L20           1 SEA ABB=ON  L18 AND 4(W)?PYRIDIN?

     FILE 'REGISTRY' ENTERED AT 17:09:08 ON 15 JAN 2008
L21           3 SEA ABB=ON  IMATINIB
L22             STRUCTURE  152459-95-5
L23           5 SEA SSS SAM L22
L24         132 SEA SSS FUL L22

     FILE 'HCAPLUS' ENTERED AT 17:10:57 ON 15 JAN 2008
L25        3170 SEA ABB=ON  L24
```

```
     FILE 'REGISTRY' ENTERED AT 17:11:50 ON 15 JAN 2008
L26           0 SEA ABB=ON  DIMETHANESULFONIC ACID/CN
                E DIMETHANESULFONIC/CN
L27           0 SEA ABB=ON  SULFONIC ACID, DIMETHAN/CN
                E SULFONIC ACID, DIMETHAN/CN

     FILE 'HCAPLUS' ENTERED AT 17:12:43 ON 15 JAN 2008
L28           0 SEA ABB=ON  L25 AND ?DIMETHANESULFONIC?

     FILE 'REGISTRY' ENTERED AT 17:14:45 ON 15 JAN 2008
L29           0 SEA ABB=ON  SULFONIC ACID METHAN/CN
                E SULFONIC ACID METHAN/CN
                E SULFONIC ACIDS DIMETHAN/CN
                E SULFONIC ACIDS, DIMETHAN/CN

     FILE 'HCAPLUS' ENTERED AT 17:15:47 ON 15 JAN 2008
L30     1719794 SEA ABB=ON  (L25 OR ?CRYSTALLIN? OR ?XRAY? OR X(W)RAY?(W)?POWDE
                R?(W)?DIFFRACT? OR CUKA OR ?RADIAT?)
L31         103 SEA ABB=ON  L25 AND (?CRYSTALLIN? OR ?XRAY? OR X(W)RAY?(W)?POWD
                ER?(W)?DIFFRACT? OR CUKA OR ?RADIAT?)
L32           0 SEA ABB=ON  L31 AND CUKA
L33           0 SEA ABB=ON  L31 AND CUKALPHA
L34          11 SEA ABB=ON  L31 AND ?SULFONIC?(W)ACID

     FILE 'REGISTRY' ENTERED AT 17:20:47 ON 15 JAN 2008
L35           1 SEA ABB=ON  75-75-2/RN

     FILE 'HCAPLUS' ENTERED AT 17:25:14 ON 15 JAN 2008
L36          11 SEA ABB=ON  L31 AND (20% OR 20 OR 17.23 OR 17.62 OR 18.72 OR
                19.90 OR 20.23 OR 21.25 OR 21.59 OR 22.05 OR 22.44 OR 23.38 OR
                23.68 OR 24.48 OR 25.41 OR 26.10 OR 28.39 OR 16.91 OR 17.60 OR
                18.69 OR 19.78 OR 20.50 OR 21.60 OR 22.00 OR 22.70 OR 23.07 OR
                24.49 OR 26.13 OR 27.25)
L37          18 SEA ABB=ON  L34 OR L36
L38          16 SEA ABB=ON  L37 AND (PRD<20060929 OR PD<20060929)

     FILE 'HCAPLUS' ENTERED AT 17:26:52 ON 15 JAN 2008
L39        1508 SEA ABB=ON  L30 AND (CUKA OR CUKALPHA)
L40           7 SEA ABB=ON  L39 AND ?SULFONIC?(W)ACID
L41          25 SEA ABB=ON  L37 OR L40
L42          23 SEA ABB=ON  L41 AND (PRD<20060929 OR PD<20060929)

     FILE 'USPATFULL' ENTERED AT 17:28:30 ON 15 JAN 2008
L43         756 SEA ABB=ON  L41 AND (PRD<20060929 OR PD<20060929)
L44         750 SEA ABB=ON  L43 AND (20% OR 20 OR 17.23 OR 17.62 OR 18.72 OR
                19.90 OR 20.23 OR 21.25 OR 21.59 OR 22.05 OR 22.44 OR 23.38 OR
                23.68 OR 24.48 OR 25.41 OR 26.10 OR 28.39 OR 16.91 OR 17.60 OR
                18.69 OR 19.78 OR 20.50 OR 21.60 OR 22.00 OR 22.70 OR 23.07 OR
                24.49 OR 26.13 OR 27.25)
L45          28 SEA ABB=ON  L44 AND DISULFONIC?(W)ACID

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:30:28 ON 15 JAN 2008
L46          51 DUP REMOV L42 L45 (0 DUPLICATES REMOVED)

     FILE HOME

     FILE HCAPLUS
```

FILE COVERS 1907 - 15 Jan 2008 VOL 148 ISS 3
FILE LAST UPDATED: 14 Jan 2008 (20080114/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1
DICTIONARY FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Jan 2008 (20080115/PD)
FILE LAST UPDATED: 15 Jan 2008 (20080115/ED)
HIGHEST GRANTED PATENT NUMBER: US7320143
HIGHEST APPLICATION PUBLICATION NUMBER: US2008010713
CA INDEXING IS CURRENT THROUGH 15 Jan 2008 (20080115/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Jan 2008 (20080115/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2007
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2007